Evidence map›Paper›PMID 40439920›Full record

ArticleClinical and experimental medicine2025

Study on the impact of CD4

Yingxia Gu, Kai Dong, Ju Deng, Bianbian Qiao, Dan Liu, Zhifang Xu, Hongwei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yingxia GuShanxi Medical University, 56 Xinjian South Road, Taiyuan, Shanxi Province, China.
Kai DongShanxi Medical University, 56 Xinjian South Road, Taiyuan, Shanxi Province, China.
Ju DengShanxi Medical University, 56 Xinjian South Road, Taiyuan, Shanxi Province, China.
Bianbian QiaoShanxi Medical University, 56 Xinjian South Road, Taiyuan, Shanxi Province, China.
Dan LiuShanxi Medical University, 56 Xinjian South Road, Taiyuan, Shanxi Province, China.
Zhifang XuLaboratory of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China. Xu_zfang@163.com.
Hongwei WangShanxi Medical University, 56 Xinjian South Road, Taiyuan, Shanxi Province, China. wanghw68@hotmail.com.

Funding

the Central Guidance for Local Science and Technology Development Projects in Shanxi Province YDZJSX2021B009the National Natural Science Foundation of China 81670126
6 · The paper itself

Abstract

This study investigates the impact of minimal residual disease (MRD) on relapse in patients with acute myeloid leukemia (AML), focusing on its interaction with immune cells function. A total of 49 AML patients were enrolled in this prospective study and categorized into four groups: MRD

Indexed as

CD4-Positive T-LymphocytesLeukemia, Myeloid, AcuteT-Lymphocyte SubsetsAdolescentAdultAgedApoptosisCell Line, TumorCell ProliferationFemaleFlow CytometryHumansInterleukin-10MaleMiddle AgedNeoplasm, ResidualInterleukin-10Acute myeloid leukemiaImmune functionMinimal residual diseaseRelapse introduction

Identifiers

PMID40439920
PMCPMC12122554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.